Vivos Revenue Rises 24% to $6.4 Million Amid Payer Contract Negotiations
Key Facts
On November 16, Vivos Therapeutics reported results for the three and nine months ended September 30, 2026, posting quarterly revenue of $6.4 million, up 24% from the previous quarter. The company said revenue for the nine months reached $16.7 million, compared with $13.6 million in the same period of 2025. Third-quarter revenue was higher than $5.2 million in the second quarter, but remained below the $6.8 million recorded in the third quarter of 2025. In its filing, the company said legacy payer contracts that had not been reviewed for some time are currently being renegotiated. Vivos engaged third-party professional advisers to assist with the negotiations as it seeks to improve revenue and liquidity.
The revenue mix reflects a shift toward services, with performance varying across business lines. Quarterly service revenue rose 1% to $4.6 million, while product revenue fell to $1.8 million from $2.2 million in the year-earlier quarter. The company attributed the decline in product revenue to its strategic shift away from selling devices to dentists under its Integrated Provider program. For the nine months, service revenue increased 57% to $12.1 million. Vivos said the growth was driven primarily by sleep tests and the resulting treatment services in its Nevada operations.
Quarterly revenue growth was not matched by an improvement in gross margin year over year. The margin was 52% in the third quarter, compared with 58% in the same period of 2025, which the company attributed to lower product revenue. However, the nine-month gross margin improved to 56% from 55% in the comparable period. On costs, quarterly operating expenses fell 17% to $7.2 million from $8.7 million a year earlier. The decline included a $1.4 million reduction in general and administrative expenses, with lower professional fees, equipment maintenance and office expenses, as well as reduced marketing and sales expenses.
The operating loss in the third quarter narrowed 18% to $3.9 million from $4.7 million in the year-earlier quarter, while the operating loss for the nine months widened to $15.3 million from $13.5 million. The quarterly net loss was $2.0 million, compared with $5.4 million a year earlier. That figure, however, included about $2.9 million in other income from the reversal of a previously recorded liability related to the employee retention tax credit. As for liquidity, the company reported cash and cash equivalents of $0.2 million on September 30. It said that balance would not be sufficient to fund operations and strategic objectives for the twelve months following the issuance of the financial statements, and that the absence of additional funding raises substantial doubt about its ability to continue as a going concern.
Cash flow data show continued pressure on available resources: Vivos used about $12.3 million in cash for operating activities during the first nine months of 2026, compared with $11.5 million in the same period of 2025. In its filing, the company said it would need additional funding during the first quarter of 2027 to meet its cash needs. It also aims to move toward cash flow positive operations in 2027. These objectives accompany efforts to reduce costs and renegotiate payer contracts. On September 29, the company estimated that increasing rates under negotiated contracts could add between $2.4 million and $5.6 million in revenue, with “very little” associated cost.
The business diversification plan also depends on services tied to the diagnosis and treatment of sleep disorders. Initiatives include EEG testing and treatment for insomnia and sleep disorders unrelated to sleep apnea, along with the distribution and setup of PAP and CPAP therapies and remote monitoring for CPAP users. The company expects these initiatives collectively to begin supporting revenue and margins in the fourth quarter of 2026, with their contribution increasing during 2027. In its estimates published in September, Vivos forecast that the EEG initiative would reach an annualized revenue run rate of between $1.5 million and $3.0 million in the fourth quarter of 2026. It also expected the remote monitoring program to reach an annualized revenue run rate of $3.5 million by the first quarter of 2027.
The cost reduction plan includes estimated annual savings of about $3.6 million beginning in the fourth quarter of 2026, while additional cuts took effect on October 1. In the company's recent history, Vivos completed the SOD Sciences deal on October 16, then Nasdaq notified it on October 20 that it had regained compliance with the minimum stockholders’ equity requirement, with compliance monitoring continuing. The company's shares closed at $0.0822 on November 16, compared with a close of $0.098 on November 13. Vivos invited investors and interested parties to a conference call to discuss its strategic initiatives and their expected effects on near-term revenue growth and cash burn, at 5:00 p.m. Eastern time on November 16. The stated need for additional funding during the first quarter of 2027 remains part of the financial picture the company presented with its results.